Cellular expression of interleukin 2 [IL-2] and its receptor [IL-2R, CD25] in lung tumours

• Autorzy: Kasprzak A , Olejniczak K. , Przybyszewska W. , Zabel M.
• Języki publikacji: EN

Abstrakty

EN

In view of the unclear prognostic and diagnostic role of interleukin 2 (IL-2) and its receptor in human tumours, we examined the cellular expression of IL-2 and of the subunit α of its receptor (IL-2Rα, CD25) in relation to the proliferative activity of various subtypes of lung tumours. The immunocytochemical ABC technique was applied to archival tissue material of neuroendocrine lung tumours: lung carcinoids, including typical carcinoids (TC), atypical carcinoids (AC) and small-cell lung cancers (SCLC) and squamous cell lung cancers (non-small cell lung cancers, NSCLC). Expression of IL-2 was detected in all types of lung tumours. The highest frequency of IL-2 expression (93%) was noted and the most pronounced semi-quantitatively evaluated expression of IL-2 was detected in AC tumour cells. The expression was more pronounced as compared to neoplastic SCLC (p = 0.01) and NSCLC cells (p = 0.005). The results suggest a negative correlation between IL-2 expression and the proliferative activity of tumour cells (evaluated by expression of Ki-67) in AC. The frequency of detection of IL-2 receptor (IL-Rα, CD25) was the highest in NSCLC (94%). Semi-quantitative expression of IL-2R, like that of IL-2, also dominated in the group of atypical lung carcinoids but manifested a significant difference only as compared to typical carcinoids (p = 0.014). Within the groups of tumours studied no correlation could be detected between cellular expressions of IL-2 and IL-2R. Our results demonstrate variable expression of IL-2 and its receptor in various types of lung tumours, but no simple relationship could be detected between tissue expression of the markers and proliferative activity. Appraisal of the diagnostic and/or prognostic significance of the results requires further study.

Słowa kluczowe

EN

histology; interleukin 2; cellular expression; receptor; interleukin 2R receptor; immunocytochemistry; CD25 receptor; lung tumour; lung cancer; cancer; human tumour

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2007
• Tom: 66
• Numer: 3
• Opis fizyczny: p.159-166,fig.,ref.

Twórcy

autor

Kasprzak A

• University of Medical Sciences, Swiecickiego 6, 60-781 Poznan, Poland

autor

Olejniczak K.

autor

Przybyszewska W.

autor

Zabel M.

Bibliografia

• 1. Bohm J, Koch S, Gais P, Jutting U, Prauer HW, Hofler H (1996) Prognostic value of MIB-1 in neuroendocrine tumours of the lung. J Pathol, 178: 402–409.
• 2. Brown DC, Gatter KC (1990) Monoclonal antibody Ki-67: its use in histopathology. Histopathology, 17: 489–503.
• 3. Cheutin T, O’Donohue MF, Beorchia A, Klein C, Kaplan H, Ploton D (2003) Three-dimensional organization of pKi-67: a comparative fluorescence and electron tomography study using fluoronanogold. J Histochem Cytochem, 51: 1411–1423.
• 4. De Vita F, Turitto G, di Grazia M, Frattolillo A, Catalano G (1998) Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small cell lung cancer. Tumori, 84: 33–38.
• 5. Fisher JR, Schindel M, Stein N, Lahm H, Gallati H, Krammer PH, Drings P (1995) Selective suppression of cytokine secretion in patients with small-cell lung cancer. Ann Oncol, 6: 921–926.
• 6. Garcia-Tunnon J, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M (2004) Interleukin-2 and its receptor complex (α, β and γ chains) in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Res, 6: 1–7.
• 7. Gatter KC, Dunnill MS, Gerdes J, Stein H, Mason DY (1986) New approach to assessing lung tumours in man. J Clin Pathol, 39: 590–593.
• 8. Hsu S, Raine L, Fanger H (1981) Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem, 29: 577–580.
• 9. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, Uyemura C, Modlin R, Wollman J, Dubinett SM (1995) Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res, 55: 3847–3853.
• 10. Kuhn DJ, Dou QP (2005) The role of interleukin-2 receptor alpha in cancer. Front Biosci, 10: 1462–1474.
• 11. Kuhn DJ, Smith DM, Pross S, Whiteside TL, Dou QP (2003) Overexpression of interleukin-2 receptor in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability. J Cell Biochem, 89: 824–836.
• 12. Lin WC, Yasumura S, Suminami Y, Sung M-W, Nagashima S, Stanson J, Whiteside TL (1995) Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth. J Immunol, 155: 4805–4816.
• 13. Lissoni P, Rizzo V, Barni S, Rescaldani R, Rovelli F, Biondi A, Archili C, Frigerio F, Tancini G (1989) Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlated. Int J Biol Markers, 4: 170–173.
• 14. Lissoni P, Barni S, Rovelli F, Viviani S, Maestroni GJ, Conti A, Tancini G (1990) The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer, 26: 33–36.
• 15. Lissoni P, Barni S, Rovelli F, Tancini G (1991) Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentration. Preliminary report. Oncology, 48: 125–127.
• 16. Marino P, Fruttero A, Preatoni A, Bossi B, Ferrigno D, Buccheri GF (1991) Inadequate T-cell help and increased concentration of IL-2 receptor in lung cancer. Chest, 100 (Suppl): 40S.
• 17. Meazza R, Marciano S, Sforzini S, Orengo AM, Coppolecchia M, Musiani P, Ardizzoni A, Santi L, Azzarone B, Ferrini S (1996) Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in smallcell lung cancer. Br J Cancer, 74: 788–795.
• 18. Minami Y, Kono T, Miyazaki T, Taniguchi T (1993) The IL-2 receptor complex: its structure, function and target genes. Ann Rev Immunol, 11: 245–267.
• 19. Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal bone marrows. Science, 193: 1007–1008.
• 20. Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin, 49: 33–64.
• 21. Probst M, Buer J, Ganser A, Atzpodien S (2003) Interleukin-2 in hematology and oncology: state of the art. Cancer, 8: 5–19.
• 22. Reed JC (1997) Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematological malignances. Semin Hematol, 34: 9–19.
• 23. Reichert TE, Watkins S, Stanson J, Johnson JT, Whiteside TL (1998) Endogenous IL-2 in cancer cells: a marker of cellular proliferation. J Histochem Cytochem 46: 603–611
• 24. Remmele W, Stegner HE (1987) Vorschlag zur einheitlichen Definition eines immunoreactiven Score (IRS) fur den Immunohistochemichen Ostrogenrezeptor — Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe, 8, 138–140.
• 25. Schmitz I, Krueger A, Baumann S, Schultze-Bergkamen H, Krammer PH, Kirchhoff S (2003) An IL-2-dependent switch between CD95 signaling pathways sensitizes primary human T cells toward CD95-mediated activation-induced cell death. J Immunol, 171: 2930–2936.
• 26. Siwicki JK, Hedberg Y, Nowak R, Loden M, Zhao J, Landberg G, Roos G (2000) Long term cultured IL-2 dependent T-cell lines demonstrate p16 (INK4a) overexpression, normal pRb/p53, and upregulation of cyclins E or D2. Exp Gerontol, 35: 375–388.
• 27. Smith KA (1988) Interleukin-2: inception, impact, and implication. Science, 240: 1169–1176.
• 28. Strauchen JA, Breakstone BA (1986) IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am J Pathol, 126: 506–512.
• 29. Tisi E, Lissoni P, Angeli M, Arrigoni C, Corno E, Cassina E, Ballabio D, Benetti C, Barni S, Tancini G (1992) Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. Cancer, 69: 2458–2462.
• 30. Weidmann E, Sacchi M, Plaisance S, Heo DS, Yasamura S, Lin WC, Johnson JT, Heberman RB, Azzarone B, Whiteside TL (1992) Receptors for Interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res, 52: 5963–5970.
• 31. Yesner R (2001) Heterogeneity of so-called neuroendocrine lung tumors. Exp Mol Pathol, 70: 179–182.